natgillin/translations-raw huggingface dataset:
Sanofi Winthrop Industrie 56 route de Choisy au bac F-60205 Compiegne Cedex France
Sanofi Winthrop Industrie 56, route de Choisy au bac F-60205 Compiegne Cedex Francuska
Sanofi Winthrop Industrie 56, Route de Choisy au Bac F-60205 Compiegne Cedex France
Sanofi Winthrop Industrie 56, Route de Choisy au Bac F-60205 Compiegne Cedex Francuska‌
Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main Germany
Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt na Majni Njemačka
Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt am Main Germany.
Sanofi-Aventis Deutschland GmbH 65926 Frankfurt na Majni Njemačka
Sanofi-Aventis Deutschland GmbH Industriepark Höchst
Sanofi-Aventis Deutschland GmbH Industriepark Höchst‌
Sanofi-Aventis Deutschland GmbH Industriepark Höchst, D- 65926 Frankfurt Germany
Sanofi-Aventis Deutschland GmbH Industriepark Höchst, D-65926 Frankfurt Njemačka
Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany
Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt na Majni, Njemačka.
Sanofi-Aventis Deutschland GmbH, D-65926 Frankfurt am Main, Germany.
Sanofi-Aventis Deutschland GmbH D-65926 Frankfurt na Majni, Njemačka
Sanquin Plasma Products B.V., Plesmanlaan 125
Stichting Sanquin Bloedvoorziening, Plesmanlaan 125
Sanquin Plasma Products B.V., Plesmanlaan 125 NL, 1066 CX Amsterdam, the Netherlands
Sanquin Plasma Products B.V., Plesmanlaan 125, NL-1066 CX Amsterdam, Nizozemska
Sanquin Plasma Products B.V., Plesmanlaan 125, NL-1066 CX Amsterdam, the Netherlands
Sanquin Plasma Products B.V., Plesmanlaan 125, NL-1066 CX Amsterdam, Nizozemska
Saponin 0.31 mg.
Saponina 0,31 mg
Saponin 0.4 mg
Saponin 0,4 mg
SAPPHIRE I and II
(0,96-1,04)
SAPPHIRE-I – genotype 1, treatment-naïve, without cirrhosis
SAPPHIRE-I – prethodno neliječeni ispitanici s infekcijom genotipom 1, bez ciroze
SAPPHIRE-II was a randomised, global multicentre, double-blind, placebo-controlled trial conducted in 394 subjects with genotype 1 chronic hepatitis C virus infection without cirrhosis who did not achieve SVR with prior treatment with pegIFN/RBV.
SAPPHIRE-I bilo je randomizirano, globalno, multicentrično, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno u 631 prethodno neliječenog odraslog ispitanika s kroničnom infekcijom virusom hepatitisa C genotipa 1 bez ciroze.
Saquinavir
akvinavir
Saquinavir
usporedbe)
Saquinavir (saquinavir/ritonavir 1000/100 mg bid)
Sakvinavir (sakvinavir/ritonavir 1000/100 mg dvaput na dan)
Saquinavir (strong CYP3A4 inhibitor)
Sakvinavir (snaţan inhibitor CYP3A4)
Saquinavir 1,200 mg SD (soft
Sakvinavir 1200 mg SD (meka
Saquinavir 1000 mg twice daily with ritonavir 100 mg twice daily in ART experienced patients.
Sakvinavir 1000 mg dva puta na dan s ritonavirom 100 mg dva puta na dan kod bolesnika koji su prethodno primali antiretrovirusno liječenje.
Saquinavir 600 mg SD (hard
Sakvinavir 600 mg SD (tvrda
Saquinavir AUC ↑ 348%.
(nepojačani sakvinavir)
Saquinavir AUC ↑ 348%.
Sakvinavir AUC ↑ 348%.
Saquinavir AUC ↑ 82%
Sakvinavir AUC ↑ 82
saquinavir AUC ↓ 6%
sakvinavir AUC ↓ 6
Saquinavir AUC ↓ 76%
Sakvinavir AUC ↓ 76
Saquinavir AUC  1% Saquinavir Cmax  7%
Sakvinavir AUC  1% Sakvinavir Cmax  7% Sakvinavir Cmin 
Saquinavir AUC  1% Saquinavir Cmax  7% Saquinavir Cmin 
Sakvinavir AUC  1% Sakvinavir Cmax  7% Sakvinavir Cmin 
Saquinavir AUC  15% Saquinavir Cmax  9%
Sakvinavir AUC  15% Sakvinavir Cmax  9
Saquinavir AUC  30% Saquinavir Cmax  25% Saquinavir Cmin 
Sakvinavir AUC  30% Sakvinavir Cmax  25% Sakvinavir Cmin 
Saquinavir AUC0-12  13% (90% CI: 31 - 9↑)
Sakvinavir AUC0-12  13% (90% CI: 31 - 9↑)
Saquinavir AUC:  360 %
AUC sakvinavira:  360
Saquinavir AUC:  500 %
AUC sakvinavira:  500
Saquinavir AUC:  620 %
AUC sakvinavira:  620
Saquinavir Cmax ↑ 106 %
Ketokonazol Cmax ↑ 45
Saquinavir Cmax ↑ 75%
Sakvinavir Cmax ↑ 75
Saquinavir Cmax ↑ 9% (90% CI: 27 - 61↑ )
Sakvinavir Cmax ↑ 9% (90% CI: 27 - 61↑ )
saquinavir Cmax ↓ 6%
sakvinavir Cmax ↓ 6
Saquinavir Cmax ↓ 70%
Sakvinavir Cmax ↓ 70
Saquinavir Cmax  15% (90% CI: 32 - 7↑)
Sakvinavir Cmax  15% (90% CI: 32 - 7↑)
saquinavir Cmin ↓ 18%
sakvinavir Cmin ↓ 18
Saquinavir Cmin ↓ 82%
Sakvinavir Cmin ↓ 82
Saquinavir Cmin  24% (remained above the target threshold for
Sakvinavir Cmin  24% (ostao je iznad ciljnog praga za djelotvorno liječenje)
Saquinavir Cmin  78%
Sakvinavir Cmin  78
Saquinavir Cmin:  190 %
Cmin sakvinavira:  190
Saquinavir Cmin:  450 %
Cmin sakvinavira:  450
Saquinavir concentrations may be
Mogu se povećati koncentracije sakvinavira.
Saquinavir Ctrough  49 % (8 hours post dose)
Sakvinavir AUC  51% Sakvinavir Ctrough  49% (8 sati poslije doziranja)
Saquinavir levels may increase on stopping St. John’s wort, and the dose of saquinavir may need adjusting.
Nakon prestanka uzimanja gospine trave koncentracija sakvinavira može se povisiti pa može biti potrebna prilagodba doze sakvinavira.
Saquinavir should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus (see section 5.3).
Sakvinavir se tijekom trudnoće smije koristiti samo ako moguća korist liječenja opravdava mogući rizik za fetus (vidjeti dio 5.3).
saquinavir soft capsule 1200 mg tid
Sakvinavir meka kapsula 1200 mg tid
Saquinavir 
Opijatni analgetici
Saquinavir 
Sakvinavir 
Saquinavir  Efavirenz 
Sakvinavir  Efavirenz 
Saquinavir  Enfuvirtide 
Sakvinavir  Enfuvirtid 
Saquinavir/ritonavir
Sakvinavir/ritonavir
Saquinavir/ritonavir
Sakvinavir/ritonavir Tipranavir/ritonavir Atazanavir
Saquinavir/ritonavir and Nevirapine Teva can be co- administered without dose adjustments.
Teva mogu se istodobno primjenjivati bez prilagodbe doze.
saquinavir/ritonavir can be
akvinavir/ritonavir mogu se
Saquinavir/ritonavir/Efavirenz
NNRTI/efavirenz
Saquinavir/ritonavir/Emtricitabine
sakvinavir/ritonavir/emtricitabin
Saquinavir/ritonavir/Tenofovir disoproxil fumarate
akvinavir/ritonavir/tenofovirdizoproksil fumarat
Saquinavir4
Ritonavir Sakvinavir4
Saquinavir4 Ritonavir
Sakvinavir4
Saquinavir:
Sakvinavir:
Saquinavir: careful monitoring for any occurrence of drug toxicity and /or lack of anti-viral
Sakvinavir: paţljivo praćenje radi mogućeg razvoja toksičnosti
Saquinavir: careful monitoring for any occurrence of drug toxicity and /or lack of anti-viral efficacy, and dose adjustment if required
lijeka i/ili izostanka antivirusne djelotvornosti te po potrebi prilagoĎavanje doze
Saquinavir: comparison of
Sakvinavir: usporedba
sarcoidosis
sarkoidoza
Sarcoidosis*, rheumatoid arthiritis (new or aggravated)
arkoidoza*, reumatoidni artritis (novootkriveni ili pogoršanje)
Sarcoidosis*, rheumatoid arthritis (new or aggravated)
arkoidoza*, reumatoidni artritis (novootkriveni ili pogoršanje)
Sarcoidosis, thyroiditis
arkoidoza, tiroiditis
Sarkhej Bavla Highway Moraiya; Taluka: Sanand,
Sarkhej Bavla Highway Moraiya; Taluka: Sanand,‌
Sarolaner is active against adult fleas (Ctenocephalides felis and Ctenocephalides canis) as well as several tick species such as Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, Rhipicephalus sanguineus and the mite Sarcoptes scabiei.
Sarolaner djeluje na odrasle buhe (Ctenocephalides felis i Ctenocephalides canis) te na brojne vrste krpelja (Dermacentor reticulatus, Dermacentor variabilis, Ixodes hexagonus, Ixodes holocyclus, Ixodes ricinus, Ixodes scapularis, Rhipicephalus sanguineus, Amblyomma americanum, Amblyomma maculatum) i grinja (Sarcoptes scabiei, Demodex canis i Otodectes cynotis).
Sarolaner is well tolerated in Collies with a deficient multidrug-resistance-protein 1 (MDR1 -/-) following single oral administration at 5 times the recommended dose.
Collie s nedovoljnim MDR 1-/-(multidrug-resistance-protein) dobro su podnijeli sarolaner prilikom jednokratne peroralne primjene 5 puta veće doze od preporučene.
Sarolaner kills fleas before they can lay eggs and so helps to reduce contamination of the dog’s environment.
Sarolaner ubija buhe prije nego što uspiju izleći jajašča te tako pomaže pri smanjivanju kontaminacije okruženja psa.
Sarolaner kills these parasites that have ingested the dog’s blood by acting on their nervous system.
Sarolaner ubija ove parazite koji su popili krv psa tako što djeluje na njihov živčani sustav.
Sarolaner was determined to have low clearance (0.12 ml/min/kg) and a moderate volume of distribution (2.81 l/kg).
Sarolaner ima niski bubrežni klirens (0,12 ml/min/kg), te umjereni volumen raspodjele (2,81 L / kg).
Sarolaner was dose proportional in Beagle dogs when dosed from the intended use dose of 2–4 mg/kg, to 20 mg/kg.
Sarolaner je bio proporcionalan dozi kod pasa pasmine Beagle, kod doziranja propisane doze 2 do 4mg/kg do doze 20 mg/kg tjelesne težine.
Sat.
Sub.
Sat.
ub.
SAT2 Saudi Arabia
AFTOVAXPUR DOE
SAT2 Saudi Arabia ................................................................................................................... ≥ 6 PD50*
SAT2 Saudi Arabia ....................................................................................................................≥ 6PD50
Saturable binding studies suggest a membrane receptor for imiquimod exists on responding immune cells.
Ispitivanja pokazuju da na reaktivnim imunološkim stanicama postoji membranski receptor za imikvimod.
Save the outer needle cover as you will need it to remove the needle after the injection.
Sačuvajte vanjski poklopac, jer će Vam trebati kad budete uklanjali iglu nakon korištenja.
Savene 20 mg/ml powder for concentrate and diluent for solution for infusion (dexrazoxane)
Savene 20 mg/ml prašak za koncentrat i otapalo za otopinu za infuziju (deksrazoksan)
Savene 20 mg/ml powder for concentrate and diluent for solution for infusion.
Savene 20 mg/ml prašak za koncentrat i otapalo za otopinu za infuziju.
Savene 20 mg/ml powder for concentrate dexrazoxane
Savene 20 mg/ml prašak za koncentrat deksrazoksan
Savene also contains sodium (1.61 g/500 ml) which may be harmful to people on a low-sodium diet.
Savene također sadrži natrij (1,61 g/500 ml) koji može biti štetan za pacijente na prehrani sa smanjenim unosom natrija.
Savene contains potassium and sodium.
Savene sadrži kalij i natrij.
Savene contains the active substance dexrazoxane, which acts as an antidote to anti-cancer medicines called anthracyclines.
Savene sadrži djelatnu tvar deksrazoksan koja djeluje kao protulijek za antikancerogene lijekove antracikline.
Savene diluent
Otapalo lijeka Savene
Savene diluent also contains sodium (1.61 g/500 ml) which may be harmful to patients on a controlled sodium diet.
Otapalo lijeka Savene također sadrži natrij (1,61 g/500 ml) koji može biti štetan za pacijente na prehrani s kontroliranim unosom natrija.
Savene diluent contains potassium (98 mg/500 ml).
Otapalo lijeka Savene sadrži kalij (98 mg/500 ml).
Savene diluent:
Otapalo lijeka Savene:
Savene infusion will be given at the sametime every day of your treatment.
Infuzija lijeka Savene bit će dana u isto vrijeme svaki dan Vašeg liječenja.
Savene is an anti-cancer agent and the normal procedures for proper handling and disposal of anticancer medicines should be adopted, namely:
Savene je sredstvo protiv raka te je potrebno primijeniti uobičajene postupke za pravilno rukovanje i zbrinjavanje lijekova protiv raka:
Savene is available as an emergency kit consisting of 10 vials of Savene powder and 3 bottles of Savene diluent.
Savene je dostupan kao set za hitne slučajeve koji sadrži 10 bočica praška Savene i 3 boce otapala lijeka Savene.
Savene is indicated for the treatment of anthracycline extravasation in adults.
Savene je indiciran za liječenje ekstravazacije antraciklina u odraslih osoba.
Savene is used to treat anthracyline extravasationin adults.
Savene se koristi za liječenje ekstravazacije antraciklina u odraslih.
Savene must be administered under the supervision of a physician experienced in the use of anti- cancer medicinal products.
Savene se mora primjenjivati pod nadzorom liječnika s iskustvom u uporabi antitumorskih lijekova.
Savene powder:
Prašak Savene:
Savene should be administered aseptically as a 1-2 hours infusion under room temperature and normal light conditions.
Savene treba primijeniti aseptički kao infuziju koja traje 1-2 sata pri sobnoj temperaturi uz uobičajene uvjete osvjetljenja.
Savene should not be administered to children below the age of 18 years.
Savene se ne smije davati djeci mlađoj od 18 godina.
Savene should only be given to you if you have an extravasation in connection with anthracycline-containing chemotherapy.
Savene Vam se treba dati samo ako ste imali ekstravazaciju povezanu s terapijom koja sadrži antraciklin.
Savene will be given to you under the control of a doctor experienced in the use of anticancer treatments.
Savene će Vam biti dan pod nadzorom liječnika iskusnog u liječenju raka.
SAVOR was a CV outcome trial in 16,492 patients with HbA1c ≥6.5% and <12% (12959 with established CV disease; 3533 with multiple risk factors only) who were randomised to saxagliptin (n=8280) or placebo (n=8212) added to regional standards of care for HbA1c and CV risk factors.
3533 bolesnika koji su samo imali višestruke faktora rizika), koji su bili randomizirani na saksagliptin (N=8280) ili placebo (8212) kao dodatak regionalnom standardnom liječenju za HbA1c i kardiovaskularne faktore rizika.
Saxa 5 mg daily add-on to metformin;
Saksagliptin 5 mg na dan kao dodatak metforminu;
Saxa 5 mg daily add-on to metformin; Study CV181014 (n=186)
Saksagliptin 5 mg na dan kao dodatak metforminu;
Saxa 5 mg daily initial combination with metformin; Study CV1810393
Ispitivanje CV181014 (n=186)
Saxa 5 mg daily, Study CV181057:
Saksagliptin 5 mg na dan, Ispitivanje
Saxagliptin (n=127) provided significant improvements in HbA1c and PPG compared with the placebo (n=128).
Saksagliptin (n=127) je značajno poboljšao vrijednosti HbA1c i PPG a u usporedbi s placebom (n=128).
Saxagliptin (N=8280)
saksagliptin (N=8280)
Saxagliptin + Dapagliflozin +
Saksagliptin + dapagliflozin +
Saxagliptin 5 mg
Saksagliptin 5 mg
Saxagliptin 5 mg add-on to insulin with or without metformin provided significant improvements after 24 weeks in HbA1c and PPG compared with placebo add-on to insulin with or without metformin.
Saksagliptin od 5 mg pridodan inzulinu sa ili bez metformina doveo je do značajnog poboljšanja vrijednosti HbA1c i PPG-a nakon 24 tjedna u usporedbi s placebo pridodanom inzulinu sa ili bez metformina .
Saxagliptin add-on combination therapy with insulin (with or without metformin)
Saksagliptin kao dodatak kombiniranoj terapiji s inzulinom (sa ili bez metformina)
Saxagliptin add-on combination therapy with insulin (with or without metformin)
Saksagliptin pridodan kombiniranoj terapiji s inzulinom (sa ili bez metformina)
Saxagliptin add-on combination therapy with metformin and sulphonylurea
Saksagliptin kao dodatak kombiniranoj terapiji s metforminom i sulfonilurejom
Saxagliptin add-on combination therapy with metformin and sulphonylurea
Saksagliptin pridodan kombiniranoj terapiji metforminom i sulfonilurejom
Saxagliptin add-on to glibenclamide therapy
Saksagliptin pridodan terapiji glibenklamidom
Saxagliptin add-on to metformin compared with sitagliptin add-on to metformin
Saksagliptin pridodan terapiji metforminom u usporedbi sa sitagliptinom pridodanom terapiji metforminom
Saxagliptin add-on to metformin therapy
Saksagliptin pridodan terapiji metforminom
Saxagliptin add-on to thiazolidinedione therapy
Saksagliptin pridodan terapiji tiazolidindionom
Saxagliptin and metformin have a negligible influence on the ability to drive and use machines.
Saksagliptin i metformin mogu zanemarivo utjecati na sposobnost upravljanja vozilima i rada na strojevima.
Saxagliptin as add-on to metformin plus a sulph- onylurea
saksagliptin kao dodatak metforminu plus sulfonilureji
Saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus - thrombolysis in myocardial infarction (SAVOR) study
Ocjena vaskularnih ishoda uz primjenu saksagliptina kod bolesnika sa šećernom bolešću – tromboliza kod infarkta miokarda (SAVOR ispitivanje)
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus- Thrombolysis in Myocardial Infarction (SAVOR) Study
Ispitivanje ocjene vaskularnih ishoda uz primjenu saksagliptina u bolesnika sa šećernom bolešću – trombolize u infarktu miokarda (SAVOR)
Saxagliptin in combination with a fixed, intermediate dose of a sulphonylurea (glibenclamide 7.5 mg) was compared to titration to a higher dose of glibenclamide (approximately 92% of patients in the placebo plus glibenclamide group were up-titrated to a final total daily dose of 15 mg).
Saksagliptin u kombinaciji s fiksnom, srednje visokom dozom sulfonilureje (glibenklamid 7,5 mg) uspoređivao se s glibenklamidom čija doza se titracijski povećavala (u približno 92% bolesnika u skupini koja je primala placebo i glibenklamid doza se titracijski povećavala do konačne ukupne dnevne doze od 15 mg).
Saxagliptin in combination with metformin as initial therapy
Saksagliptin u kombinaciji s metforminom kao početna terapija
Saxagliptin in combination with metformin for glycaemic control
Saksagliptin u kombinaciji s metforminom za kontrolu glikemije
Saxagliptin is a highly potent (Ki: 1.3 nM), selective, reversible, competitive, DPP4 inhibitor.
Saksagliptin je potentni (Ki: 1,3 nm), selektivni, reverzibilni, kompetitivni inhibitor enzima DPP-4.
Saxagliptin is eliminated by both renal and hepatic pathways.
Saksagliptin se eliminira i putem bubrega i putem jetre..
Saxagliptin monotherapy
monoterapija saksagliptino m
Saxagliptin or metformin has a negligible influence on the ability to drive and use machines.
Saksagliptin i metformin neznatno utječu na sposobnost upravljanja vozilima i rada na strojevima.
Saxagliptin significantly decreased HbA1c compared with placebo; the HbA1c change for saxagliptin was -0.9% at Week 12 (HbA1c change of -0.4% for placebo).
Saksagliptin je značajno smanjio HbA1c u usporedbi s placebom; promjena vrijednosti HbA1c uz saksagliptin iznosila je –0,9% u 12. tjednu (promjena HbA1c od –0,4% za placebo).
Saxagliptin twice daily add-on to metformin therapy
Saksagliptin dvaput na dan kao dodatak terapiji metforminom
Saxagliptin with a sulphonylurea (glibenclamide)
aksagliptin sa sulfonilurejom (glibenklami- dom)
Saxagliptin with a thia- zolidinedione
aksagliptin s tiazolidindio- nom
Saxagliptin with metformin1
aksagliptin s metforminom1
Saxagliptin/dapagliflozin combination: In the pooled safety analysis, the incidence of adverse events related to decreased renal function was 2.0 % subjects in the saxagliptin plus dapagliflozin plus metformin group, 1.8 % subjects in the saxagliptin plus metformin group, and 0.6 % subjects in the dapagliflozin plus metformin group.
Kombinacija saksagliptin/dapagliflozin: Prema objedinjenim analizama sigurnosti, incidencija štetnih događaja povezanih sa smanjenom bubrežne funkcijom bila je 2,0% kod ispitanika u skupini liječenoj kombinacijom saksagliptin plus dapagliflozin plus metformin, 1,8% kod ispitanika u skupini liječenoj kombinacijom saksagliptin plus metformin i 0,6% kod ispitanika u skupini liječenoj kombinacijom dapagliflozin plus metformin.
Saxagliptin/dapagliflozin combination: Of the 1169 subjects treated in the pooled safety data from the 3 clinical trials, 1007 subjects (86.1 %) were aged < 65 years, 162 subjects (13.9 %) were aged
Kombinacija saksagliptin/dapagliflozin: Od 1169 liječenih ispitanika čiji su podaci bili uključeni u objedinjene podatke o sigurnosti iz 3 klinička ispitivanja, 1007 ispitanika (86,1%) bilo je u dobi
Saxagliptin/dapagliflozin combination: The reported adverse events of vulvovaginitis, balanitis and related genital infections from pooled safety analysis were reflective of the safety profile of dapagliflozin.
Kombinacija saksagliptin/dapagliflozin: Prijavljeni štetni događaji vulvovaginitisa, balanitisa, i povezanih genitalnih infekcija iz objedinjenih podataka o sigurnosti odraz su sigurnosnog profila dapagliflozina.
Saxagliptin: Concomitant administration of saxagliptin with the moderate inhibitor of CYP3A4/5 diltiazem, increased the Cmax and AUC of saxagliptin by 63 % and 2.1-fold, respectively, and the corresponding values for the active metabolite were decreased by 44 % and 34 %, respectively.
Saksagliptin: Istodobna primjena saksagliptina s umjerenim inhibitorom CYP3A4/5 diltiazemom povećala je Cmax saksagliptina za 63%, a AUC za 2,1 puta, dok su se iste vrijednosti za aktivni metabolit smanjile za 44% odnosno 34%.
Saxagliptin: Elderly patients (65–80 years) had about 60 % higher saxagliptin AUC than young patients (18–40 years).
Saksagliptin: Kod starijih je bolesnika (65 – 80 godina) AUC saksagliptina bio približno 60% veći nego kod mlađih bolesnika (18 – 40 godina).
SBP (mmHg)2, 3
Sistolički krvni tlak (mmHg)2, 3
SBP (mmHg)3
Sistolički krvni tlak (mmHg)3
SBS patients are to be kept under close surveillance according to clinical treatment guidelines.
Bolesnike sa SKC-om treba sukladno kliničkim smjernicama pomno nadzirati.
SC
. s.c.
SC (cattle) IM (pigs)
s.c. (goveda) i.m. (svinje)
SC (cattle), IM (pigs)
s.c. (goveda) i.m. (svinje)
SC Bayer SRL
Bayer, spol. s r.o.
SC for Chronic Lymphocytic Leukaemia
s.c. za kroničnu limfocitnu leukemiju
SC for Non-Hodgkin’s Lymphoma
s.c. za ne-Hodgkinov limfom
SC formulation in administration system
Supkutana formulacija u sustavu za primjenu
SC Montero Vet SRL Bd Iuliu Maniu 602B, sector 6, Bucuresti, Romania
Grochowska 278, klatka B lok.
SC or IV use only.
Samo za potkožnu primjenu ili primjenu u venu.
SC use
s.c. primjena
SC use
Za s.c. primjenu.
SC-I was a non-inferiority study that compared the efficacy and safety of tocilizumab 162 mg administered every week versus 8 mg/kg intravenous in 1262 patients with RA.
SC-I je bilo ispitivanje neinferiornosti u kojemu su se uspoređivale djelotvornost i sigurnost tocilizumaba u supkutanoj dozi od 162 mg jedanput tjedno s primjenom intravenske doze od 8 mg/kg u 1262 bolesnika s RA.
SC.
s.c
Scab
kraste
Scabs
Kraste
Scales and crusts are then carefully removed and all lesion surfaces are gently roughened.
Ljuske i kraste treba potom temeljito ukloniti i sve površine lezija nježno učiniti hrapavim.
Scales and crusts should be removed accurately and all lesion surfaces roughened gently.
Potrebno je temeljito ukloniti ljuske i kraste i sve površine lezija učiniti nježno hrapavim.
Scalp
Vlasište
Scaly, flaky, itchy and red skin
ljuskice, perutanje, svrbež i crvenilo kože
Scaly, peeling skin
ljuskice na koži i ljuštenje kože
SCAN THIS CODE TO LAUNCH
SKENIRAJTE OVAJ KOD DA BISTE OTVORILI STRANICU
Scan with pronounced beta-amyloid deposition
Slika s beta-amiloidnim depozitom izrazite gustoće
Scan without beta-amyloid deposition
Slika bez beta-amiloidnih depozita
Scar
ožiljak
scar
ožiljci
Scar tissues may develop in some patients after surgery and use of TachoSil.
Nakon kirurškog zahvata i uporabe TachoSila u nekih je bolesnika moguć razvoj ožiljkastih tkiva.
Scarf: for head and neck.
Zadržavajte se u sjeni.
Scarf: for head and neck.
Šal: za glavu i vrat.
Scarring
Ožiljci
Scarring in the kidney that may reduce kidney function
ožiljkaste promjene na bubregu koje mogu smanjiti funkciju bubrega
Scarring of the conjunctiva (the protective layer over the white of your eye) with damage where it joins to the inside of the eyelids (fornix shortening)
ožiljke spojnice (zaštitni sloj preko bjeloočnice) s oštećenjem na mjestu gdje se spaja s vjeđama iznutra (skraćivanje forniksa)
Scars
ožiljaka
SCC in MGIT® n/N (%)
SCC u MGIT® n/N (%)
SCC in the treatment area was reported in no patients (0 of 184 patients previously treated with ingenol mebutate gel) in the three prospective, observational long term 1 year follow-up studies.
Karcinom pločastih stanica na liječenom području nije prijavljen ni u jednog bolesnika (0 od 184 bolesnika prethodno liječenih ingenol mebutat gelom) u tri prospektivna, opservacijska dugoročna jednogodišnja kontrolna ispitivanja.
SCC of the skin (d), seborrheic keratosis, skin papilloma
planocelularni karcinom kože (d), seboroična keratoza, papilomi kože
SCC on solid media n/N (%)
SCC na krutoj podlozi n/N (%)